Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Bartosz, Chmielowski"'
Autor:
Chmielowski B; Bartosz Chmielowski, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Mar 20; Vol. 36 (9), pp. 835-836. Date of Electronic Publication: 2018 Feb 01.
Autor:
Karlton Wong, Fritz C. Eilber, Sarah M. Dry, Mark A. Eckardt, Jomjit Chantharasamee, Jacob J. Adashek, Arun S. Singh, Bartosz Chmielowski
Publikováno v:
Current Treatment Options in Oncology. 22
The role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an active
Autor:
Jomjit, Chantharasamee, Jacob J, Adashek, Karlton, Wong, Mark A, Eckardt, Bartosz, Chmielowski, Sarah, Dry, Fritz C, Eilber, Arun S, Singh
Publikováno v:
Current treatment options in oncologyReferences and Recommended ReadingPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance. 22(1)
The role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an active
Autor:
Lakshmi Srinivasan, Yvonne Ware, Kelledy Manson, Asaf Poran, Benjamin Trapp, Joel Greshock, Mark M. Awad, Dominik Barthelme, Dewi Harjanto, Victoria Kohler, Ying S. Ting, Richard B. Gaynor, Yuting Huang, Matthew D. Hellmann, Samantha J. Turnbull, Siwen Hu-Lieskovan, Ed Fritsch, Meghan E. Bushway, Jessica J. Lin, Lisa D. Cleary, Bartosz Chmielowski, Zhengping Huang, Michael S. Rooney, Terence W. Friedlander, Rana H. Besada, Patrick A. Ott, Zakaria S. Khondker, Mark DeMario, Kristen N. Balogh, Aung Naing, Melissa A. Moles, Riley R. Curran, Kim Margolin, Nina Bhardwaj, Tracey E. Sciuto, Jesse Z. Dong, Ramaswamy Govindan, Julian Scherer, Amy Wanamaker
Publikováno v:
Cell. 183(2)
Summary Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combina
Autor:
D Rasco, Erika Hamilton, D Vaena, Jason J. Luke, Ryan J. Sullivan, Manvi Sharma, A Elnaggar, A Adewoye, E Ileana-Dumbrava, J Olweny, J Hunter, Bartosz Chmielowski, Emerson A. Lim, A Patnaik
Publikováno v:
E-Poster viewings.
Objectives Novel therapies are needed for the treatment of pts with relapse/refractory disease following treatment with approved checkpoint inhibitors. COM701 is a 1st in class novel immune checkpoint inhibitor of PVRIG, part of the DNAM axis. Key pr
Autor:
I. Peter Shintaku, Grace Cherry, Siwen Hu-Lieskovan, Davis Y. Torrejon, Salemiz Sandoval, Blanca Homet Moreno, Lucas Barthly, Jia Pang, Thomas G. Graeber, Gabriel Abril-Rodriguez, Antoni Ribas, Xiangju Kong, Roger S. Lo, Justin Saco, Jesse M. Zaretsky, Helena Escuin-Ordinas, Ton N. Schumacher, Begoña Comin-Anduix, Elizabeth Seja, Daniel Sanghoon Shin, Phillip J. Sanchez, Willy Hugo, Kathleen Ruchalski, Beata Berent-Maoz, Paul C. Tumeh, Riccardo Mezzadra, Cristina Puig-Saus, Angel Garcia-Diaz, Bartosz Chmielowski
Publikováno v:
The New England journal of medicine, vol 375, iss 9
Zaretsky, JM; Garcia-Diaz, A; Shin, DS; Escuin-Ordinas, H; Hugo, W; Hu-Lieskovan, S; et al.(2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine, 375(9), 819-829. doi: 10.1056/NEJMoa1604958. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4157s0ms
Zaretsky, JM; Garcia-Diaz, A; Shin, DS; Escuin-Ordinas, H; Hugo, W; Hu-Lieskovan, S; et al.(2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine, 375(9), 819-829. doi: 10.1056/NEJMoa1604958. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4157s0ms
© 2016 Massachusetts Medical Society. BACKGROUND Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial obj
Autor:
Damion Nero, Sama Ahsan, Frank Xiaoqing Liu, Bruce Feinberg, Andrew J Klink, Bartosz Chmielowski
Publikováno v:
Journal of managed carespecialty pharmacy. 25(8)
The treatment landscape for patients with metastatic melanoma has changed dramatically with the introduction of novel therapies, such as targeted therapies and immunotherapies, in recent years. Health care resource utilization (HCRU) and cost data ar
Autor:
Theodore S. Nowicki, Siwen Hu-Lieskovan, Catherine S. Grasso, Xiaoyan Wang, Gardenia Cheung-Lau, Antoni Ribas, Ivan Perez Garcilazo, Paula Kaplan-Lefko, Alistair J. Cochran, Begoña Comin-Anduix, Anusha Kalbasi, Jia Pang, Beata Berent-Maoz, Ignacio Baselga Carretero, Justin Tran, Jennifer Tsoi, Mignonette H. Macabali, Bartosz Chmielowski, Paula Cabrera, Rong Rong Huang, Arun S. Singh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 25, iss 7
Purpose: Transgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d034bb7c3868fb92539e6ee64f86942f
https://escholarship.org/uc/item/8hg2h9ns
https://escholarship.org/uc/item/8hg2h9ns
Autor:
Alain C. Mita, David Martin Darst, Michael A. Postow, Angela Jain, Celia Andreu, Robert Wasserman, Robert Busby, Gerald Steven Falchook, Igor Puzanov, Erika Hamilton, Michael Szarek, Tomislav Dragovich, Narayan Lebaka, Eric K. Rowinsky, Rebecca Redman, Monica M. Mita, Masoud Tavazoie, Shubham Pant, Isabel Kurth, Olivier Rixe, Syed Ahsan Raza, Russell J. Schilder, Kevin B. Kim, R. Donald Harvey, Foster C. Gonsalves, Emerson A. Lim, James Strauss, Bartosz Chmielowski
Publikováno v:
Cancer Research. 80:CT146-CT146
Background: RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. Binding of ApoE to its receptor LRP8 robustly inhibits angiogenesis and depletes myeloid derived suppressor cells (MDS
Autor:
Beata Berent-Maoz, Paula Kaplan-Lefko, Theodore S. Nowicki, Lili Yang, Antoni Ribas, Thinle Chodon, Earl Avramis, James S. Economou, Bartosz Chmielowski, Xiaoyan Wang, Begoña Comin-Anduix, David Baltimore, Helena Escuin-Ordinas
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997), vol 41, iss 5
Nowicki, TS; Escuin-Ordinas, H; Avramis, E; Chmielowski, B; Chodon, T; Berent-Maoz, B; et al.(2018). Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. JOURNAL OF IMMUNOTHERAPY, 41(5), 248-259. doi: 10.1097/CJI.0000000000000216. UCLA: Retrieved from: http://www.escholarship.org/uc/item/8gj2r49s
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Nowicki, TS; Escuin-Ordinas, H; Avramis, E; Chmielowski, B; Chodon, T; Berent-Maoz, B; et al.(2018). Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. JOURNAL OF IMMUNOTHERAPY, 41(5), 248-259. doi: 10.1097/CJI.0000000000000216. UCLA: Retrieved from: http://www.escholarship.org/uc/item/8gj2r49s
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Adoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fbfebaf1633a54709d09fa315875e0
https://escholarship.org/uc/item/8gj2r49s
https://escholarship.org/uc/item/8gj2r49s